Technology: Prostate-specific antigen-derived MHC class II restricted peptides and their use in vaccines to treat or prevent prostate cancer

VA ID Number: 05-063

Inventor: Richard Alexander

Location: Baltimore, MD

Topic: Therapeutics/Oncology

USPTO Issue Date: 5/7/2013

Patent Number: 8,435,507

The VA has joint ownership with University of Maryland, Baltimore and Oregon Health & Science University

Contact: christopher.drabik@va.gov

Abstract: The present invention relates to immunogenic peptides derived from human prostate cancer antigen (PSA-derived peptides) and their use as vaccines to treat or prevent prostate cancer. The invention is also related to dendritic cells from a patient having prostate cancer, which dendritic cells have been exposed to one or more PSA-derived peptides, and their use to treat or prevent prostate cancer in the patient. The invention is also directed to T-cells from a patient which cells are specific for PSA-activated peptide(s), and their uses to treat or prevent prostate cancer.